// Workers AI · dad joke modeWhat did SH-BC-893 say to its date? You've got my code.

SH-BC-893
Identifiers
	IUPAC name [(2S,3R)-3-(4-octylphenyl)pyrrolidin-2-yl]methanol;
CAS Number	1841409-91-3;
PubChem CID	126720664;
Chemical and physical data
Formula	C19H31NO
Molar mass	289.463 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCC1=CC=C(C=C1)[C@H]2CCN[C@@H]2CO;
	InChI InChI=1S/C19H31NO/c1-2-3-4-5-6-7-8-16-9-11-17(12-10-16)18-13-14-20-19(18)15-21/h9-12,18-21H,2-8,13-15H2,1H3/t18-,19-/m1/s1; Key:FCFUUVQZYSWJLH-RTBURBONSA-N;

SH-BC-893 is a synthetic sphingolipid derivative which has been researched for the treatment of cancer, and also shows broad-spectrum antiviral properties as well as potential application in the treatment of obesity. It acts by decreasing cell surface expression of several different nutrient transporter proteins, which can then starve cancer cells of nutrients as well as blocking viral entry into cells via endosomal pathways.^[1]^[2]^[3]^[4]^[5]^[6]

References

↑ Kim SM, Roy SG, Chen B, Nguyen TM, McMonigle RJ, McCracken AN, et al. (November 2016). "Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways". The Journal of Clinical Investigation. 126 (11): 4088–4102. doi:10.1172/JCI87148. PMC 5096903. PMID 27669461.
↑ Finicle BT, Ramirez MU, Liu G, Selwan EM, McCracken AN, Yu J, et al. (June 2018). "Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6". Journal of Cell Science. 131 (12) jcs213314. doi:10.1242/jcs.213314. PMC 6031383. PMID 29848659.
↑ Kubiniok P, Finicle BT, Piffaretti F, McCracken AN, Perryman M, Hanessian S, et al. (March 2019). "Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs". Molecular & Cellular Proteomics. 18 (3): 408–422. doi:10.1074/mcp.RA118.001053. PMC 6398214. PMID 30482847.
↑ Jayashankar V, Selwan E, Hancock SE, Verlande A, Goodson MO, Eckenstein KH, et al. (August 2021). "Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity". EMBO Molecular Medicine. 13 (8) EMMM202013086. doi:10.15252/emmm.202013086. PMC 8350895. PMID 34231322.
↑ Finicle BT, Eckenstein KH, Revenko AS, Anderson BA, Wan WB, McCracken AN, et al. (February 2023). "Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics". Nucleic Acids Research. 51 (4): 1583–1599. doi:10.1093/nar/gkad023. PMC 9976930. PMID 36727438.
↑ Finicle BT, Perrochon AS, Chu B, Buchmeier MJ, Edinger AL (May 2026). "Endolysosomal trafficking regulator SH-BC-893 inhibits coronavirus entry in vitro and in vivo". Scientific Reports. doi:10.1038/s41598-026-51335-y. PMID 42115643.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

[1] Kim SM, Roy SG, Chen B, Nguyen TM, McMonigle RJ, McCracken AN, et al. (November 2016). "Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways". The Journal of Clinical Investigation. 126 (11): 4088–4102. doi:10.1172/JCI87148. PMC 5096903. PMID 27669461.

[2] Finicle BT, Ramirez MU, Liu G, Selwan EM, McCracken AN, Yu J, et al. (June 2018). "Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6". Journal of Cell Science. 131 (12) jcs213314. doi:10.1242/jcs.213314. PMC 6031383. PMID 29848659.

[3] Kubiniok P, Finicle BT, Piffaretti F, McCracken AN, Perryman M, Hanessian S, et al. (March 2019). "Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs". Molecular & Cellular Proteomics. 18 (3): 408–422. doi:10.1074/mcp.RA118.001053. PMC 6398214. PMID 30482847.

[4] Jayashankar V, Selwan E, Hancock SE, Verlande A, Goodson MO, Eckenstein KH, et al. (August 2021). "Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity". EMBO Molecular Medicine. 13 (8) EMMM202013086. doi:10.15252/emmm.202013086. PMC 8350895. PMID 34231322.

[5] Finicle BT, Eckenstein KH, Revenko AS, Anderson BA, Wan WB, McCracken AN, et al. (February 2023). "Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics". Nucleic Acids Research. 51 (4): 1583–1599. doi:10.1093/nar/gkad023. PMC 9976930. PMID 36727438.

[6] Finicle BT, Perrochon AS, Chu B, Buchmeier MJ, Edinger AL (May 2026). "Endolysosomal trafficking regulator SH-BC-893 inhibits coronavirus entry in vitro and in vivo". Scientific Reports. doi:10.1038/s41598-026-51335-y. PMID 42115643.

[1]

[2]

[3]

[4]

[5]

[6]

See also

References